Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

The FDA expanded the indication for the monoclonal antibody denosumab to include the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, according to a press ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

A study comparing denosumab (Prolia) with risedronate (Actone) found that denosumab could be a useful treatment option for patients newly initiating or continuing glucocorticoids who are at risk of ...

Biosimilar CT-P41 showed comparable efficacy and safety to reference denosumab for treating osteoporosis among postmenopausal women. CT-P41, a biosimilar candidate for denosumab, demonstrates efficacy ...

During the first 12 weeks of treatment, 41.1% of women on denosumab developed severe hypocalcemia compared with 2.0% of those taking oral bisphosphonates, reported a group of largely FDA researchers ...

Osteoporosis Stethoscope Denosumab injections prevent osteoporosis in patients with primary biliary cholangitis and autoimmune hepatitis, with few adverse effects. BOSTON, MA—Injections of denosumab ...

Continued denosumab treatment is associated with a lower risk for diabetes in adults with osteoporosis older than 65 years, found a large-scale cohort study in Taiwan. Denosumab, used in osteoporosis ...

Older women who received denosumab (Prolia, Amgen) for up to 10 years for osteoporosis had a low risk of osteonecrosis of the jaw (ONJ), although the risk was higher — albeit still quite small — if ...

Patients with transfusion-dependent thalassemia (TDT) and osteoporosis who were treated with denosumab had greater increases in bone mineral density in the femoral neck and lumbar spine, as well as ...

Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate ...